Oral mucositis is one of the most treatment-limiting toxicities in head and neck radiotherapy. Beyond pain and quality of life, prolonged overall treatment time is linked to poorer locoregional control — so supportive mucosal care carries genuine oncologic weight, not just palliative value.
Two well-tolerated compounds map onto this problem from different angles. Polaprezinc (zinc L-carnosine) is a mucosa-adherent chelate that acts topically at the site of injury, with several small radiotherapy and transplant studies showing reduced mucositis severity and better tolerability. L-glutamine is a metabolic substrate for epithelial renewal, with a more mixed evidence base — clinically promising in several RCTs, though larger meta-analyses disagree on effect size.
Our full clinician briefing reviews the evidence for each compound, the biological rationale for using them together, practical cautions (drug spacing, copper monitoring, hepatic/renal considerations), and a clinician-supervised REZCUE oral rinse protocol modelled on the trial formulations.
This is supportive-care information for use under a patient's oncology team — not a treatment protocol.
Click here to download the whitepaper.
